HAS-BLED Bleeding Risk Score
Predict 1-year major bleeding risk in atrial fibrillation patients on oral anticoagulation. Always paired with CHA₂DS₂-VASc to balance stroke vs bleeding risk.
HAS-BLED Score
0/9
Estimated 1-year major bleeding risk: 0.9%
Recommendation
Low bleeding risk. Anticoagulation is safe — proceed if CHA₂DS₂-VASc indicates it. Re-evaluate score annually.
Stop forgetting modifiable bleeding factors
EasyClinic surfaces patient BP trends, prescribed NSAIDs/antiplatelets, and INR control history right next to the HAS-BLED score — so you never miss a fixable risk factor.
Also Known As
What is the HAS-BLED score?
The HAS-BLED score is the most widely validated tool to estimate 1-year risk of major bleeding in atrial fibrillation patients on oral anticoagulation. It was derived from the Euro Heart Survey (Pisters 2010) and is endorsed by ESC, AHA/ACC and CSI guidelines.
The score ranges 0–9. A score ≥3 indicates "high bleeding risk" — but critically, this is a signal to address modifiable bleeding factors and increase monitoring, NOT to withhold anticoagulation.
Score Components (mnemonic: HAS-BLED)
- H — Hypertension (uncontrolled, SBP > 160)
- A — Abnormal renal (Cr > 2.6 / dialysis) or liver function (cirrhosis, bilirubin > 2× ULN, transaminases > 3× ULN). 1 point each.
- S — Stroke history
- B — Bleeding history or anaemia
- L — Labile INR (TTR < 60% on warfarin)
- E — Elderly (age > 65)
- D — Drugs: antiplatelets, NSAIDs (or alcohol — 1 point each)
Modifiable vs Non-modifiable Risk Factors
The real value of HAS-BLED is identifying modifiable factors to fix:
- Modifiable: Uncontrolled BP, labile INR (switch to DOAC), NSAIDs/antiplatelets (stop or use PPI cover), alcohol excess (counsel)
- Non-modifiable: Age, prior stroke, prior bleed, chronic renal/liver disease
If only non-modifiable factors are present, do not withhold anticoagulation — net clinical benefit usually still favours OAC.
When to use HAS-BLED
- At AF diagnosis — before starting OAC
- At every follow-up visit (factors change: new NSAID, worsening renal function, age crossing 65)
- When considering switching from warfarin to a DOAC (DOACs have lower ICH risk)
- Before adding antiplatelet (post-PCI dual or triple therapy)
Frequently Asked Questions
▸A patient has HAS-BLED 4 and CHA₂DS₂-VASc 5. Should I withhold anticoagulation?
No. Net clinical benefit still favours OAC in nearly every such case. Address modifiable factors (BP, NSAIDs, alcohol, INR control), prefer a DOAC over warfarin, and document the risk-benefit discussion with the patient.
▸Which DOAC has the lowest bleeding risk in Indian patients?
Apixaban (Eliquis, Apixaban-various generics) has the most favourable bleeding profile in head-to-head trials, particularly for major and intracranial bleeding. Dabigatran (Pradaxa) has higher GI bleeding risk. Rivaroxaban (Xarelto) is in between. All have lower ICH risk than warfarin.
▸How do I calculate TTR (time in therapeutic range) for the Labile INR criterion?
Use the Rosendaal linear interpolation method — most lab/EMR systems automate this. A TTR < 60% over the prior 6 months scores 1 point. If unavailable, ≥ 2 INRs out of range in the past 6 months is a reasonable surrogate.
▸Does prior GI bleed permanently disqualify a patient from OAC?
No. After the source is identified and treated (e.g., H. pylori eradication, endoscopic clipping, PPI), restart OAC — preferably apixaban — typically within 7–14 days. Indefinite OAC avoidance carries higher mortality than restart.
▸Should I use HAS-BLED for patients on DOACs or only warfarin?
It was validated on warfarin cohorts but is widely applied to DOAC patients as a general bleeding risk signal. The Labile INR criterion does not apply to DOACs — but uncontrolled BP, NSAIDs, alcohol, and renal function are equally relevant.
References
- Pisters R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fibrillation. Chest 2010;138(5):1093-100
- ESC Guidelines for the diagnosis and management of atrial fibrillation 2024
- AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation 2023
- Cardiological Society of India (CSI) Position Statement on NOAC use in NVAF
- Lip GYH. Implications of the CHA₂DS₂-VASc and HAS-BLED Scores for thromboprophylaxis. Am J Med 2011
Bleeding and stroke risk — at every AF visit
EasyClinic auto-runs CHA₂DS₂-VASc and HAS-BLED on every AF patient, flags modifiable bleeding factors like uncontrolled BP and NSAID co-prescription, and tracks TTR for warfarin patients.
Trusted by Indian doctors who want to stop typing
Choose the plan that fits your practice — cancel anytime.
DOCTORSCRIBE
AI Medical Scribe
₹999
/month
- ✓ Voice → prescription in 30 seconds
- ✓ 11 Indian languages (Hindi, Tamil, Telugu, etc.)
- ✓ Auto pediatric dose by weight
- ✓ ICD-10 codes, drug interactions
EASYCLINIC
Complete Clinic Platform
₹1,999
/month
- ✓ Everything in DoctorScribe, plus:
- ✓ Patient records, billing, GST invoices
- ✓ WhatsApp reminders to patients
- ✓ Multi-doctor scheduling + analytics
- ✓ All 60+ calculators built into the chart